Justine Smith MD PhD was recognized for participation on the Council of the American Academy of Ophthalmology during AAO 2015 in Las Vegas. Dr. Smith served for 6 years as a councilor for the American Uveitis Society.
The Council serves as an advisory body to the Academy’s Board of Trustees. More than 100 Academy members serve on this body and act as liaisons between their society and the Academy bringing issues identified by their societies to the attention of the Academy’s Board of Trustees. Issues are brought to the Academy Board of Trustees as Council Advisory Recommendations (CARs). Each spring the Council meets to debate and formulate its recommendations for the Academy Board.
Representatives to the Council are elected by each state society and by subspecialty societies and specialized interest groups in ophthalmology. On December 31st, Dr. Smith will conclude her term on the Academy Council. Russell Read MD PhD has been elected by the American Uveitis Society to serve as Councilor to the Academy and will begin his term on January 1, 2016 and participate at the Spring Council Meeting in conjunction with the April 13-16, 2016 Mid-Year Forum in Washington, D.C.
The American Uveitis Society announces that its Fall Meeting will be held in conjunction with the AAO Annual Meeting in Las Vegas, NV on October 15, 2015 at Treasure Island. Members and guests are invited to join the AUS for a social hour from 7 to 8 PM with the scientific meeting to follow immediately at 8 PM.
AUS members who's dues are current may attend the meeting at no charge. A guest fee of $50 is accessed for others, but is waived for non-AUS members who are the presenter of a free paper.
Dr. Emmett Cunningham will moderate “Controversies in Uveitis. Case-based comments from a non-consensus panel of experts", followed by a free paper session. The program committee invites abstracts presenting research that will not be presented at the AAO meeting. Case presentations will be considered if they are of sufficient interest. Please only submit one abstract per first author.
Abstract submission will be electronic and the submission site is now open. Submissions will close on September 30, 2015. Decisions will be made by October 9, 2015 and the corresponding author notified via email.
Sincerely,
Nisha Acharya, M.D., M.S.
nisha.acharya@ucsf.edu
Program Chair, AUS Fall Meeting
Russell W. Read, MD, PhD
rwread@gmail.com
Executive Secretary
American Uveitis Society
The 13th Congress of the International Ocular Inflammation Society will be held in San Francisco from September 25 to 27, 2015. This will be the first IOIS Congress to be held in the US. More than 25 societies focused on ocular inflammation will host sessions during the three day meeting along with IOIS Sections focused on all aspects of ocular immunology and disease. Further details can be found at the Congress website.
The National Eye Institute (NEI and US Food and Drug Administration (FDA) are holding a public Workshop on Endpoints for Ocular Inflammatory Diseases on the campus of the NIH on March 26, 2015 in the Masur Auditorium.
Details regarding the meeting can be found here:
2015 NEI/FDA Endpoints Workshop
The MUST Research Group, which successfully completed the Multicenter Uveitis Steroid Treatment (MUST) Trial is conducting two new trials, the Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial and the Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy (MERIT) Trial. Both are funded by the National Eye Institute. POINT will compare the relative efficacy of three common approaches for the regional treatment of uveitic macular edema, periocular and intravitreal triamcinolone acetonide, and the dexamethasone intravitreal implant. MERIT will evaluate the relative efficacy of intravitreal ranibizumab and intravitreal methotrexate and the dexamethasone intravitreal implant for the treatment of uveitic macular edema persisting after intravitreal triamcinolone acetonide. The POINT Trial will be initiated in Spring 2015 in clinical centers that are currently following participants in the MUST Trial Follow-up Study and to have new clinical centers selected and preparing for start-up by the time of our Research Group meeting in June 2015. The MERIT Trial will begin approximately 12 months after the start of POINT; the trials will run concurrently until POINT is completed.
Abstract submission for FOCIS 2015 closes Wednesday, January 15.
The American Uveitis Society is a member society of FOCIS, the Federation of Clinical Immunology Societies.
Interesting application for the iPhone that allows you to help a low vision person with a specific issue via a video/audio link on your iPhone.
Be My Eyes - iTunes App Store Link
The American Uveitis Society is proud to reveal its most extensive update to UveitisSociety.org since its inception. This complete revamping will result in enhanced membership customer service by allowing members to view and update their profile information, track their membership status and pay dues online, and provides an enhanced Uveitis Specialist Directory through which patients can easily access clinician contact information.
